{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:22:32Z","timestamp":1761844952496,"version":"3.37.3"},"reference-count":70,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0210297","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T18:33:44Z","timestamp":1546454024000},"page":"e0210297","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions"],"prefix":"10.1371","volume":"14","author":[{"given":"Matthew","family":"Dowling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Samuelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahaa","family":"Fadl-Alla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly C.","family":"Pondenis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Byrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"Barger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-7050","authenticated-orcid":true,"given":"Timothy M.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,1,2]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.metabol.2014.10.027","article-title":"Biomarkers for personalized oncology: recent advances and future challenges","volume":"64","author":"M. Kalia","year":"2015","journal-title":"Metabolism"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"14771","DOI":"10.3390\/ijms140714771","article-title":"Clinical advances in molecular biomarkers for cancer diagnosis and therapy","volume":"14","author":"S Sethi","year":"2013","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-2004-4_2","article-title":"Significance and integration of molecular diagnostics in the framework of veterinary practice","volume":"1247","author":"A. Aranaz","year":"2015","journal-title":"Methods Mol Biol"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/jvim.12304","article-title":"Flow cytometric characterization and clinical outcome of CD4+ T-cell lymphoma in dogs: 67 cases","volume":"28","author":"PR Avery","year":"2014","journal-title":"J Vet Intern Med"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1354\/vp.40-1-32","article-title":"Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes","volume":"40","author":"RC Burnett","year":"2003","journal-title":"Vet Pathol"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.tvjl.2010.03.011","article-title":"Use of flow cytometric immunophenotyping to refine the cytological diagnosis of canine lymphoma","volume":"188","author":"S Comazzi","year":"2011","journal-title":"Vet J"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1541-7786.MCR-14-0689","article-title":"Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer\u2014Evidence for a Relevant Model System and Urine-Based Diagnostic Test","volume":"13","author":"B Decker","year":"2015","journal-title":"Mol Cancer Res"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.tvjl.2009.07.018","article-title":"Detection of the nt230[del4] MDR1 mutation in dogs by a fluorogenic 5&apos; nuclease TaqMan allelic discrimination method","volume":"185","author":"S Klintzsch","year":"2010","journal-title":"Vet J"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1939-1676.2006.tb02864.x","article-title":"Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma","volume":"20","author":"SE Lana","year":"2006","journal-title":"J Vet Intern Med"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2460\/javma.233.6.921","article-title":"Breed distribution of the ABCB1-1Delta (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping","volume":"233","author":"KL Mealey","year":"2008","journal-title":"J Am Vet Med Assoc"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/vetsci2030231","article-title":"Comparative Aspects of BRAF Mutations in Canine Cancers","volume":"2","author":"H Mochizuki","year":"2015","journal-title":"Vet Sci"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"e0129534","DOI":"10.1371\/journal.pone.0129534","article-title":"BRAF Mutations in Canine Cancers","volume":"10","author":"H Mochizuki","year":"2015","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.tvjl.2016.05.012","article-title":"Minimal residual disease in canine lymphoma: An objective marker to assess tumour cell burden in remission","volume":"215","author":"M Sato","year":"2016","journal-title":"Vet J"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/jvim.12343","article-title":"Canine T-zone lymphoma: unique immunophenotypic features, outcome, and population characteristics","volume":"28","author":"DM Seelig","year":"2014","journal-title":"J Vet Intern Med"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/jvim.12185","article-title":"Lymphoma immunophenotype of dogs determined by immunohistochemistry, flow cytometry, and polymerase chain reaction for antigen receptor rearrangements","volume":"27","author":"L Thalheim","year":"2013","journal-title":"J Vet Intern Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1746-6148-4-32","article-title":"Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone","volume":"4","author":"JD Webster","year":"2008","journal-title":"BMC Vet Res"},{"issue":"3","key":"ref17","first-page":"241","article-title":"Prostate-specific membrane antigen as a target for cancer imaging and therapy","volume":"59","author":"AP Kiess","year":"2015","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/14737159.2016.1243057","article-title":"Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer","volume":"16","author":"M Barrio","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.5858\/arpa.2010-0740-OA","article-title":"Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme","volume":"135","author":"AG Wernicke","year":"2011","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"ref20","first-page":"2674","article-title":"Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","author":"SS Chang","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"13","key":"ref21","first-page":"3192","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","author":"SS Chang","year":"1999","journal-title":"Cancer Res"},{"issue":"1","key":"ref22","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"DA Silver","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.21037\/tau.2017.03.53","article-title":"Positron emission tomography (PET) in primary prostate cancer staging and risk assessment","volume":"6","author":"S Bednarova","year":"2017","journal-title":"Transl Androl Urol"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.semnuclmed.2016.07.006","article-title":"PSMA PET and Radionuclide Therapy in Prostate Cancer","volume":"46","author":"K Bouchelouche","year":"2016","journal-title":"Semin Nucl Med"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22040523","article-title":"Metal-Based PSMA Radioligands","volume":"22","author":"E Gourni","year":"2017","journal-title":"Molecules"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1517\/14728222.9.3.561","article-title":"Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen","volume":"9","author":"SF Slovin","year":"2005","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/PPO.0000000000000221","article-title":"Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer","volume":"22","author":"MY Teo","year":"2016","journal-title":"Cancer J"},{"issue":"24","key":"ref28","first-page":"6306","article-title":"Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays","volume":"54","author":"RS Israeli","year":"1994","journal-title":"Cancer Res"},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/clinchem\/41.12.1698","article-title":"Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen","volume":"41","author":"S Loric","year":"1995","journal-title":"Clin Chem"},{"issue":"7","key":"ref30","first-page":"1215","article-title":"Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells","volume":"3","author":"Y Zhang","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"17","key":"ref31","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1158\/1078-0432.CCR-1004-03","article-title":"Prognostic value of combined &quot;triple&quot;-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients","volume":"10","author":"R Kurek","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"9","key":"ref32","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3346\/jkms.2010.25.9.1291","article-title":"Prostate specific membrane antigen mRNA in blood as a potential predictor of biochemical recurrence after radical prostatectomy","volume":"25","author":"JY Joung","year":"2010","journal-title":"J Korean Med Sci"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10585-004-3217-0","article-title":"Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer","volume":"21","author":"CS Mitsiades","year":"2004","journal-title":"Clin Exp Metastasis"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/pros.22488","article-title":"Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy","volume":"72","author":"DR Yates","year":"2012","journal-title":"Prostate"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/pros.22727","article-title":"Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells","volume":"74","author":"LY Wu","year":"2014","journal-title":"Prostate"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/1097-0045(200101)46:1<2::AID-PROS1002>3.0.CO;2-5","article-title":"In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line","volume":"46","author":"M Anidjar","year":"2001","journal-title":"Prostate"},{"issue":"9","key":"ref37","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/jemt.20824","article-title":"Polylactide nanoparticles containing stably incorporated cyanine dyes for in vitro and in vivo imaging applications","volume":"73","author":"R Tong","year":"2010","journal-title":"Microsc Res Tech"},{"issue":"5","key":"ref38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/pros.20720","article-title":"Histopathological and immunohistochemical characterization of canine prostate cancer","volume":"68","author":"CL Lai","year":"2008","journal-title":"Prostate"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13550-015-0155-6","article-title":"The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumors and metastases","volume":"5","author":"S Chevalier","year":"2015","journal-title":"EJNMMI Res"},{"issue":"1","key":"ref40","first-page":"145","article-title":"Verification of a canine PSMA (FolH1) antibody","volume":"35","author":"S Wagner","year":"2015","journal-title":"Anticancer Res"},{"issue":"5","key":"ref41","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1021\/acsnano.5b00166","article-title":"Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy","volume":"9","author":"L Tang","year":"2015","journal-title":"ACS Nano"},{"issue":"7","key":"ref42","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.exphem.2006.04.013","article-title":"Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation","volume":"34","author":"AR Lamerato-Kozicki","year":"2006","journal-title":"Exp Hematol"},{"issue":"4","key":"ref43","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ajpath.2013.12.025","article-title":"Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization","volume":"184","author":"BH Gorden","year":"2014","journal-title":"Am J Pathol"},{"issue":"5","key":"ref44","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/labinvest.3700080","article-title":"Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium","volume":"84","author":"SP Fosmire","year":"2004","journal-title":"Lab Invest"},{"issue":"4","key":"ref45","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/vetsci2040388","article-title":"Pathobiology of Hemangiosarcoma in Dogs: Research Advances and Future Perspectives","volume":"2","author":"JH Kim","year":"2015","journal-title":"Vet Sci"},{"issue":"5","key":"ref46","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1939-1676.2000.tb02262.x","article-title":"Treatment of canine hemangiosarcoma: 2000 and beyond","volume":"14","author":"CA Clifford","year":"2000","journal-title":"J Vet Intern Med"},{"issue":"5","key":"ref47","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2460\/javma.251.5.559","article-title":"Evaluation of clinical and histologic factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and adjuvant chemotherapy: 30 cases (2011\u20132014)","volume":"251","author":"AS Moore","year":"2017","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"ref48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2460\/javma.232.4.553","article-title":"Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003\u20132005)","volume":"232","author":"TN Hammond","year":"2008","journal-title":"J Am Vet Med Assoc"},{"issue":"6","key":"ref49","first-page":"706","article-title":"Epidemiologic, clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985)","volume":"193","author":"C Prymak","year":"1988","journal-title":"J Am Vet Med Assoc"},{"issue":"5","key":"ref50","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1751-0813.2009.00421.x","article-title":"Cytopathological and histopathological diagnosis of canine splenic disorders","volume":"87","author":"N Christensen","year":"2009","journal-title":"Aust Vet J"},{"issue":"4","key":"ref51","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1476-5829.2011.00298.x","article-title":"Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*","volume":"10","author":"DH Thamm","year":"2012","journal-title":"Vet Comp Oncol"},{"issue":"5","key":"ref52","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/labinvest.3700080","article-title":"Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium","volume":"84","author":"SP Fosmire","year":"2004","journal-title":"Laboratory Investigation"},{"issue":"1","key":"ref53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.rvsc.2005.09.005","article-title":"Biological and molecular characterization of a canine hemangiosarcoma-derived cell line","volume":"81","author":"DH Thamm","year":"2006","journal-title":"Res Vet Sci"},{"issue":"2","key":"ref54","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1593\/neo.03334","article-title":"Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model","volume":"6","author":"N Akhtar","year":"2004","journal-title":"Neoplasia"},{"issue":"2","key":"ref55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/pros.2990120204","article-title":"Growth of a spontaneous canine prostatic adenocarcinoma in vivo and in vitro: isolation and characterization of a neoplastic prostatic epithelial cell line, CPA 1","volume":"12","author":"CL Eaton","year":"1988","journal-title":"Prostate"},{"issue":"11","key":"ref56","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/pros.20408","article-title":"New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft","volume":"66","author":"BE LeRoy","year":"2006","journal-title":"Prostate"},{"issue":"1","key":"ref57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0300985813505879","article-title":"When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry\u2014the red, brown, and blue technique","volume":"51","author":"JA Ramos-Vara","year":"2014","journal-title":"Vet Pathol"},{"issue":"4","key":"ref58","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<739::AID-CNCR16>3.0.CO;2-T","article-title":"Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide","volume":"83","author":"GH Hinkle","year":"1998","journal-title":"Cancer"},{"key":"ref59","article-title":"Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer","author":"CD Fankhauser","year":"2018","journal-title":"World J Urol"},{"issue":"3","key":"ref60","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ucl.2018.03.016","article-title":"Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging","volume":"45","author":"MS Hofman","year":"2018","journal-title":"Urol Clin North Am"},{"issue":"5","key":"ref61","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3348\/kjr.2018.19.5.819","article-title":"Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges","volume":"19","author":"SW Oh","year":"2018","journal-title":"Korean J Radiol"},{"issue":"16","key":"ref62","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/pros.21390","article-title":"A three-gene panel on urine increases PSA specificity in the detection of prostate cancer","volume":"71","author":"M Rigau","year":"2011","journal-title":"Prostate"},{"issue":"6","key":"ref63","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/CBM-2009-0109","article-title":"Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers","volume":"5","author":"VN Talesa","year":"2009","journal-title":"Cancer Biomark"},{"issue":"7","key":"ref64","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.tcm.2015.01.013","article-title":"Circulating endothelial cells in coronary artery disease and acute coronary syndrome","volume":"25","author":"DE Schmidt","year":"2015","journal-title":"Trends Cardiovasc Med"},{"key":"ref65","first-page":"364738","article-title":"Circulating endothelial cells and chronic kidney disease","volume":"2014","author":"K Zhang","year":"2014","journal-title":"Biomed Res Int"},{"issue":"4","key":"ref66","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1939-165X.2009.00152.x","article-title":"Immunomagnetic isolation of canine circulating endothelial and endothelial progenitor cells","volume":"38","author":"TB Wills","year":"2009","journal-title":"Vet Clin Pathol"},{"issue":"5","key":"ref67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051359","article-title":"Recent Advances in Prostate Cancer Treatment and Drug Discovery","volume":"19","author":"E Nevedomskaya","year":"2018","journal-title":"Int J Mol Sci"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2741\/4193","article-title":"Antibody-drug conjugates targeting prostate-specific membrane antigen","volume":"19","author":"WC Olson","year":"2014","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"9","key":"ref69","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00259-017-3716-2","article-title":"Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617","volume":"44","author":"H Ahmadzadehfar","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"ref70","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/MOU.0000000000000486","article-title":"Prostate-specific membrane antigen theranostics: therapy with lutetium-177","volume":"28","author":"J Ferdinandus","year":"2018","journal-title":"Curr Opin Urol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0210297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T11:49:55Z","timestamp":1605959395000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0210297"}},"subtitle":[],"editor":[{"given":"Douglas H.","family":"Thamm","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,2]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0210297","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,1,2]]}}}